Sanofi Consumer Health care India Limited (BSE: 544250; NSE: SANOFICONR) reported a 12% year-on-year increase in revenue to ₹2,631 million for the third quarter of 2026, supported by 19% growth in domestic sales and improved performance across key brands.
The company’s profit before tax rose 22% year-on-year to ₹1,027 million, while earnings per share (EPS) increased by ₹5.95, representing a 22% growth. Managing Director Himanshu Bakshi said the performance reflected disciplined strategy execution, volume expansion and market share gains across key brands. He added that investments in brand building, distribution expansion and engagement with health care professionals were helping the company reach more consumers.
For the nine months ended 2026, revenue from operations grew 16% year-on-year to ₹7,280 million. Domestic sales increased 15%, aided by a relaunch, while export sales grew 19%. Profit before tax for the period rose 24%.
In Kolkata, the growth highlights opportunities for consumer health care products across retail pharmacies and health care outlets. Demand for allergy management, digestive wellness, pain care and multivitamins could support market expansion, while wider distribution may improve product access across the city.
Sanofi Consumer Health care India became a separate legal entity following its demerger from Sanofi India Limited on June 1, 2024. Its key brands include Allegra, De PURA, Avil and Combiflam.
